Skip to Content

Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer Treatment

Trastuzumab deruxtecan is an antibody-drug conjugate which has shown effectiveness in patients with HER2-low disease. In this MEDtalk Giuseppe Curigliano’s presents results from a phase three trial (DESTINY-Breast04) investigating the effectiveness and safety profile of trastuzumab deruxtecan which might should be considered in treatment algorithms for these patients.

Giuseppe Curigliano

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top